A targeted therapy for pancreatic cancer is showing promising survival outcomes in advanced disease, offering a potential breakthrough in one of the deadliest tumor types.
The pan-RAS inhibitor daraxonrasib, designed to target multiple RAS mutations, demonstrated encouraging efficacy in previously treated pancreatic ductal adenocarcinoma (PDAC). Over 90% of PDAC tumors are driven by KRAS mutations, historically considered undruggable.
In the Phase I/II trial, 168 patients with advanced RAS-mutant pancreatic cancer received daily oral daraxonrasib up to 300 mg. At that dose, approximately 30% of patients achieved an objective tumor response, and about 90% experienced disease control. Median duration of response exceeded eight months.
Phase III topline data reported a median overall survival of 13.2 months with daraxonrasib versus 6.7 months for standard chemotherapy.
Adverse events were common, including rash, nausea, fatigue, and mucositis, with Grade 3 or higher events in about 30% of patients.
The ongoing Phase III RASolute 302 trial is now comparing daraxonrasib directly with standard second-line chemotherapy in metastatic pancreatic cancer.